Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER-2 Gene Amplification”

66 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 66 results

Testing effectiveness (Phase 2)Looking for participantsNCT05867251
What this trial is testing

Study of AVZO-021 in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorHR+/HER2- Breast CancerHR+, HER2-, Advanced Breast Cancer+6 more
Avenzo Therapeutics, Inc. 430
Testing effectiveness (Phase 2)Study completedNCT00356811
What this trial is testing

Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast Cancer

Who this might be right for
Neoplasms, Breast
GlaxoSmithKline 57
Early research (Phase 1)UnknownNCT04660929
What this trial is testing

CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

Who this might be right for
HER2-positiveAdenocarcinomaBile Duct Cancer+28 more
Carisma Therapeutics Inc 48
Testing effectiveness (Phase 2)Ended earlyNCT00479856
What this trial is testing

Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer

Who this might be right for
Relapsed Breast CancerNeoplasms, Breast
GlaxoSmithKline 9
Not applicableUnknownNCT03947736
What this trial is testing

Dynamic Monitoring of HER2 and ctDNA Specific Mutations in Patients With Recurrent or Metastatic Breast Cancer by Digital PCR

Who this might be right for
Recurrent or Metastatic Breast Cancer
Chinese Academy of Medical Sciences 200
Early research (Phase 1)Ended earlyNCT05511844
What this trial is testing

Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors

Who this might be right for
HER2-positive Breast CancerHER-2 Protein OverexpressionHER-2 Gene Amplification+1 more
Orum Therapeutics USA, Inc. 25
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07570966
What this trial is testing

Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Who this might be right for
Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid TumorsMetastatic Castration-resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals 217
Testing effectiveness (Phase 2)UnknownNCT05135715
What this trial is testing

RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression)

Who this might be right for
Melanoma, Stage IIHER2-positiveAdvanced Melanoma
RemeGen Co., Ltd. 50
Early research (Phase 1)Looking for participantsNCT07361562
What this trial is testing

A Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor, AdultERBB2 Altered Breast CancerERBB2 Gene Amplification+3 more
Cogent Biosciences, Inc. 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT04818333
What this trial is testing

SHR-A1811 in Subjects With Advanced Non-small Cell Lung Cancer

Who this might be right for
Advanced Non-small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd. 157
Early research (Phase 1)Active Not RecruitingNCT03065387
What this trial is testing

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

Who this might be right for
Advanced Malignant Solid NeoplasmEGFR Gene AmplificationEGFR Gene Mutation+7 more
M.D. Anderson Cancer Center 93
Not applicableEnded earlyNCT03137693
What this trial is testing

Preoperative Stereotactic Ablative Body Radiotherapy (SABR) for Early-Stage Breast Cancer

Who this might be right for
Breast CancerBreast Cancer FemaleBreast Adenocarcinoma
H. Lee Moffitt Cancer Center and Research Institute 20
Testing effectiveness (Phase 2)Study completedNCT00006089
What this trial is testing

Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Who this might be right for
Endometrial AdenocarcinomaERBB2 Gene AmplificationRecurrent Uterine Corpus Carcinoma+2 more
National Cancer Institute (NCI) 34
Testing effectiveness (Phase 2)Looking for participantsNCT06726148
What this trial is testing

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Who this might be right for
Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid Tumors
Novartis Pharmaceuticals 280
Not applicableLooking for participantsNCT06813456
What this trial is testing

Implementation of Solid Digital PCR to Support Gold-standard Methods for Evaluation of HER2 Amplification Status: Focus on HER2-low Subtype

Who this might be right for
Breast Cancer
IRCCS Azienda Ospedaliero-Universitaria di Bologna 234
Testing effectiveness (Phase 2)Looking for participantsNCT07288359
What this trial is testing

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Who this might be right for
Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid TumorsMetastatic Castration-resistant Prostate Cancer
Novartis Pharmaceuticals 205
Early research (Phase 1)Ended earlyNCT03410927
What this trial is testing

TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities

Who this might be right for
Advanced Solid Tumors With HER2 AbnormalitiesAdvanced Solid Tumors With HER3 Abnormalities
Taiho Oncology, Inc. 19
Testing effectiveness (Phase 2)UnknownNCT00842998
What this trial is testing

Efficacy Study of Single Agent Trastuzumab or Lapatinib to Treat HER2-Overexpressing Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Azienda Ospedaliera Ordine Mauriziano di Torino 120
Testing effectiveness (Phase 2)Study completedNCT02004769
What this trial is testing

Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric Cancer

Who this might be right for
Stomach NeoplasmsNeoplasms MetastasisERBB2 Gene Amplification
Sun Yat-sen University 67
Testing effectiveness (Phase 2)Study completedNCT03602079
What this trial is testing

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Who this might be right for
HER2-positive Breast CancerHER2 Gene MutationHER-2 Gene Amplification+41 more
Klus Pharma Inc. 49
Load More Results